Science Letter
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Science Letter
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alzheimer Disease
Phase III clinical trial for treatment of Alzheimer disease continues
July 12th, 2005
Neurochem Inc. (NRMX) announced that its independent safety review board (ISRB) has issued a second recommendation to continue the company's North American phase III clinical trial for Alzhemed, an investigational product candidate for the treatment of Alzheimer disease (AD). "This additional positive recommendation by the Independent Safety Review Board, reinforces our previous findings on the safety and tolerability of Alzhemed," said Denis Garceau, PhD, senior vice president, drug development. "Over 900 patients have been enrolled and the trial is on track for completion as planned." Neurochem's ISRB for Alzhemed is made up of independent medical...
Source: Science Letter (2005-07-12)
|
